IMMP

$0.00

(

+0.00%

)
Quote details

stock

Immutep Ltd ADR

NASDAQ | IMMP

1.81

USD

+$0.00

(

+0.00%

)

At Close (As of Nov 25, 2025)

$266.42M

Market Cap

-

P/E Ratio

-0.27

EPS

$2.71

52 Week High

$1.32

52 Week Low

HEALTHCARE

Sector

IMMP Chart

Recent Chart
Price Action

IMMP Technicals

Tags:

IMMP Earnings

Yearly Income Statement (As of Jun 30, 2025)

Field Value (None)
Gross Profit -$56M
Total Revenue $5M
Cost Of Revenue $61M
Costof Goods And Services Sold $61M
Operating Income -$126M
Selling General And Administrative $8.6M
Research And Development $61M
Operating Expenses $70M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.1M
Income Before Tax -$61M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -
Comprehensive Income Net Of Tax -
Ebit -$65M
Ebitda -$63M
Net Income -$61M

Revenue & Profitability

Earnings Performance

IMMP Financials

yearly Balance Sheet (As of Jun 30, 2025)

Field Value (None)
Total Assets $157M
Total Current Assets $149M
Cash And Cash Equivalents At Carrying Value $67M
Cash And Short Term Investments $67M
Inventory -
Current Net Receivables $7.5K
Total Non Current Assets $7.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets $7.1M
Intangible Assets Excluding Goodwill $7.1M
Goodwill $110K
Investments -
Long Term Investments -
Short Term Investments $62M
Other Current Assets $19M
Other Non Current Assets -
Total Liabilities $13M
Total Current Liabilities $13M
Current Accounts Payable $5.5M
Deferred Revenue -
Current Debt -
Short Term Debt $1.3M
Total Non Current Liabilities $589K
Capital Lease Obligations -
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $1.6M
Other Current Liabilities $5.9M
Other Non Current Liabilities -
Total Shareholder Equity $144M
Treasury Stock -
Retained Earnings -$444M
Common Stock $535M
Common Stock Shares Outstanding $146M

yearly Cash Flow (As of Jun 30, 2025)

Field Value (None)
Operating Cashflow -$62M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $2.4M
Capital Expenditures $46K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$39M
Cashflow From Financing -$525K
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$61M

yearly Income Statement (As of Jun 30, 2025)

Field Value (None)
Gross Profit -$56M
Total Revenue $5M
Cost Of Revenue $61M
Costof Goods And Services Sold $61M
Operating Income -$126M
Selling General And Administrative $8.6M
Research And Development $61M
Operating Expenses $70M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $2.1M
Income Before Tax -$61M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -
Comprehensive Income Net Of Tax -
Ebit -$65M
Ebitda -$63M
Net Income -$61M

IMMP News

IMMP Profile

Immutep Ltd ADR Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Immutep Ltd ADR is an innovative biotechnology company based in Sydney, Australia, focused on the development of cutting-edge immunotherapy treatments targeting cancer and autoimmune diseases. The company is advancing its lead product candidates, which are designed to modulate immune responses and enhance the body’s ability to fight tumors. With a robust pipeline and strategic partnerships, Immutep is well-positioned to disrupt the oncology landscape and leverage significant market opportunities as it progresses through various stages of clinical trials.

LPTX
+368.57%
$2.05
RUBI
+54.22%
$0.23
NVDA
-2.59%
$177.82
CETY
+116.82%
$2.32
IVP
+7.05%
$0.17
INHD
-43.98%
$0.26
ONDS
-3.21%
$8.44
GOOGL
+1.52%
$323.44
NIO
-4.34%
$5.50
VHAI
0.00%
$0.00
PLUG
-0.51%
$1.95
ASST
-1.76%
$1.11
TSLA
+0.38%
$419.40
AMD
-4.14%
$206.13
AXDX
-61.36%
$0.03
AAL
+2.74%
$13.46
AEHL
+26.48%
$3.20
INTC
+0.11%
$35.83
PMCB
+36.92%
$0.89
BTG
+3.83%
$4.33
CMND
-19.39%
$0.16
DNN
+6.46%
$2.47
SOFI
+3.39%
$28.33
BYND
-0.62%
$0.85
F
+1.62%
$13.17
GOOG
+1.62%
$323.64
ADAP
-15.14%
$0.05
BITF
-0.71%
$2.77
VSA
-22.78%
$0.14
BMNR
-7.04%
$28.91
HBAN
+1.69%
$16.18
AAPL
+0.38%
$276.97
KVUE
+1.61%
$17.03
LNAI
-14.96%
$1.08
CLSK
+2.96%
$11.82
WULF
+10.37%
$13.94
T
+0.93%
$25.86
BTBT
-1.31%
$2.26
GRAB
-0.19%
$5.24
SOND
-23.45%
$0.12
BAC
+1.05%
$52.48
CHR
+2.26%
$0.04
RGTI
-1.84%
$26.08
RMBL
+60.50%
$3.21
OSRH
+25.67%
$0.81
AGNC
+0.97%
$10.40
MARA
-0.35%
$11.17
AMZN
+1.49%
$229.67
PFE
+1.98%
$25.72
LNW
-3.71%
$86.22
IREN
-2.10%
$47.47
ADD
-25.47%
$0.05
CIFR
+4.84%
$17.52
RIG
+0.74%
$4.05
ACHR
-0.80%
$7.38
PLTR
+0.80%
$163.55
RELI
-9.77%
$0.65
KSS
+42.53%
$22.42
DVLT
-8.67%
$2.21
AMCR
+0.47%
$8.51
NFLX
-2.40%
$104.40
SRM
+53.27%
$10.30
NVVE
+12.50%
$0.27
AVGO
+1.87%
$385.03
VNRX
-9.96%
$0.29
AUTL
+12.09%
$1.39
CCL
+3.87%
$25.72
SNAP
-0.52%
$7.64
WBD
+0.43%
$22.96
BMNU
-13.72%
$6.35
NVO
+4.64%
$47.06
BBD
+1.72%
$3.54
YGMZ
-82.37%
$0.18
RIVN
+2.57%
$15.56
PCG
-1.37%
$15.73
ORCL
-1.62%
$197.03
NOK
-0.49%
$6.06
CMG
+7.08%
$33.40
WLGS
-5.57%
$0.04
MSFT
+0.63%
$476.99
MTSR
-0.35%
$70.50
CRWV
-3.13%
$71.29
CAN
-4.88%
$0.91
BABA
-2.31%
$157.01
META
+3.77%
$636.22
VALE
+0.82%
$12.19
VZ
+0.94%
$40.59
BTE
-2.16%
$3.17
QBTS
-2.25%
$22.59
AFMD
-34.94%
$0.18
COMP
-0.94%
$10.50
AZI
-3.66%
$0.06
TWOH
0.00%
$0.00
HPQ
-0.24%
$24.32
IPG
-2.52%
$25.06
DKNG
+7.57%
$31.67
MRK
+5.23%
$105.66
SMCI
-2.52%
$32.48
HOOD
+0.52%
$115.57
ICU
+4.19%
$0.31
LPTX
+368.57%
$2.05
RUBI
+54.22%
$0.23
NVDA
-2.59%
$177.82
CETY
+116.82%
$2.32
IVP
+7.05%
$0.17
INHD
-43.98%
$0.26
ONDS
-3.21%
$8.44
GOOGL
+1.52%
$323.44
NIO
-4.34%
$5.50
VHAI
0.00%
$0.00
PLUG
-0.51%
$1.95
ASST
-1.76%
$1.11
TSLA
+0.38%
$419.40
AMD
-4.14%
$206.13
AXDX
-61.36%
$0.03
AAL
+2.74%
$13.46
AEHL
+26.48%
$3.20
INTC
+0.11%
$35.83
PMCB
+36.92%
$0.89
BTG
+3.83%
$4.33
CMND
-19.39%
$0.16
DNN
+6.46%
$2.47
SOFI
+3.39%
$28.33
BYND
-0.62%
$0.85
F
+1.62%
$13.17
GOOG
+1.62%
$323.64
ADAP
-15.14%
$0.05
BITF
-0.71%
$2.77
VSA
-22.78%
$0.14
BMNR
-7.04%
$28.91
HBAN
+1.69%
$16.18
AAPL
+0.38%
$276.97
KVUE
+1.61%
$17.03
LNAI
-14.96%
$1.08
CLSK
+2.96%
$11.82
WULF
+10.37%
$13.94
T
+0.93%
$25.86
BTBT
-1.31%
$2.26
GRAB
-0.19%
$5.24
SOND
-23.45%
$0.12
BAC
+1.05%
$52.48
CHR
+2.26%
$0.04
RGTI
-1.84%
$26.08
RMBL
+60.50%
$3.21
OSRH
+25.67%
$0.81
AGNC
+0.97%
$10.40
MARA
-0.35%
$11.17
AMZN
+1.49%
$229.67
PFE
+1.98%
$25.72
LNW
-3.71%
$86.22
IREN
-2.10%
$47.47
ADD
-25.47%
$0.05
CIFR
+4.84%
$17.52
RIG
+0.74%
$4.05
ACHR
-0.80%
$7.38
PLTR
+0.80%
$163.55
RELI
-9.77%
$0.65
KSS
+42.53%
$22.42
DVLT
-8.67%
$2.21
AMCR
+0.47%
$8.51
NFLX
-2.40%
$104.40
SRM
+53.27%
$10.30
NVVE
+12.50%
$0.27
AVGO
+1.87%
$385.03
VNRX
-9.96%
$0.29
AUTL
+12.09%
$1.39
CCL
+3.87%
$25.72
SNAP
-0.52%
$7.64
WBD
+0.43%
$22.96
BMNU
-13.72%
$6.35
NVO
+4.64%
$47.06
BBD
+1.72%
$3.54
YGMZ
-82.37%
$0.18
RIVN
+2.57%
$15.56
PCG
-1.37%
$15.73
ORCL
-1.62%
$197.03
NOK
-0.49%
$6.06
CMG
+7.08%
$33.40
WLGS
-5.57%
$0.04
MSFT
+0.63%
$476.99
MTSR
-0.35%
$70.50
CRWV
-3.13%
$71.29
CAN
-4.88%
$0.91
BABA
-2.31%
$157.01
META
+3.77%
$636.22
VALE
+0.82%
$12.19
VZ
+0.94%
$40.59
BTE
-2.16%
$3.17
QBTS
-2.25%
$22.59
AFMD
-34.94%
$0.18
COMP
-0.94%
$10.50
AZI
-3.66%
$0.06
TWOH
0.00%
$0.00
HPQ
-0.24%
$24.32
IPG
-2.52%
$25.06
DKNG
+7.57%
$31.67
MRK
+5.23%
$105.66
SMCI
-2.52%
$32.48
HOOD
+0.52%
$115.57
ICU
+4.19%
$0.31

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.